Harvard University professor and cancer institute director Ronald DePinho has been named the next president of The University of Texas MD Anderson Cancer Center in Houston.
DePinho currently is director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute and he is a professor of medicine and genetics at Harvard. He will take over the position in September for John Mendelsohn, who announced he would step down from the presidency last December. Lynda Chin, DePinho's wife and Belfer's current scientific director, also will join the faculty at MD Anderson.
Sequenom has appointed Beckman Coulter CFO and Senior VP of Finance Charles Slacik to serve on its board of directors. Slacik formerly was executive VP and CFO at Watson Pharmaceuticals and senior VP and CFO at the medical technologies company C.R. Bard. Sequenom said in a US Securities and Exchange Commission filing this week that it has granted Slacik a non-qualified stock option to buy 40,000 shares of the company's common stock at $7.89 per share, the market valuation at the date of the grant, and will provide him with additional compensation.